Solid Biosciences (SLDB) announced that the European Commission, acting upon the positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products, has granted orphan drug designation to SGT-003 for the treatment of Duchenne muscular dystrophy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences Adjusts Board Classes in Governance Move
- Solid Biosciences price target raised to $12 from $11 at JPMorgan
- 3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts
- Solid Biosciences: Strong SGT-003 Clinical Profile, Emerging Pipeline, and Robust Cash Runway Underpin Buy Rating
- Evolving Tax Rules and New Excise Levies Threaten Solid Biosciences’ Profitability and Cash Flows